< Back

January, 2017

Brand Attributes Driving Access Decisions Vary by Stakeholder and Hematologic Cancer Type

DecisionEdge|Market Access Brand Value Proposition | Research Released on 1/6/2017

Health Strategies Group’s predictive analysis model reveals that attributes driving access decisions vary by stakeholder and hematologic cancer type.

The ability to extend survival and reduce adverse-events drives access decisions for many health plans across hematologic cancer types. However, cost pressures drives increased influence of therapy costs among CML and CLL cancer types. 

Ability to extend survival is largest determinant of access within oncology groups across CML, multiple myeloma, and CLL treatments. 

Attributes Driving Access Decisions Vary by Stakeholder and Cancer Type

Download Research Slide

 

These and other findings can be found in Health Strategies Group’s recently released research DecisionEdge|Market Access Brand Value Proposition: Hematology Brand Attribute Opportunity Assessment & Outlook 2018.  

Key Topics Covered in this research:

  • Brand attributes that influence access decisions
  • Stakeholder perceptions of brand performance on key attributes
  • Recent clinical trial data and the impact on stakeholder perceptions of brand value
  • New attributes emerging in clinical trials and potential near-term impact on access decisions
  • Assessment of perceived value of currently marketed and new entrants over the next 24 months

Download Research Agenda

 

Visit our DecisionEdge|Market Access Brand Value Proposition webpage to learn more about this research.

 

Looking for more? Read related research findings

When Multiple Options Exist, Oncologists Typically Select Group Pathways

More Pathway Programs Expand to Include Complete Networks of Plan Oncologists

Disclaimer

 

Please complete the form to have this document sent to your email.

 

Please complete the form to have this document sent to your email.